Oral malaria pill study in adults without symptoms
Part of Infections clinical trials.
This Phase 1 study tests how safe a combination oral medicine (ZY19489 with ferroquine) is in adults who carry malaria in their blood but have no symptoms. It also studies how the body absorbs and processes the medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18–55 years and you weigh at least 45 kg
- You have an asymptomatic (no fever/illness) Plasmodium falciparum infection seen on a microscope test
- You must be able to swallow tablets and attend scheduled study visits and lab tests
- You must agree not to donate blood from joining until follow-up ends
- You must sign informed consent (or have a witnessed consent if you can’t sign)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.
This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.
This trial studies how well and how safely different anti-malaria medicines work for people who have uncomplicated malaria caused by Plasmodium falciparum. You may be eligible if you have a confirmed infection with a certain parasite level and do not have signs of severe disease or major health conditions.
This study compares a combination of three medicines to treat uncomplicated malaria, to see if it works as well and is as well tolerated as a two-medicine combination. You may join if you have a specific type of malaria infection in a mild form and meet safety requirements.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This study tests how the body processes a single dose of the antimalarial drug tafenoquine in healthy adults. It will help doctors understand how the drug works and how it is broken down, which may lead to better ways to prevent malaria.
Hear when a new Asymptomatic Condition trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.